Results of the preclinical multicenter randomized controlled paclitaxel-induced neuropathy prevention replication study (PINPRICS)
Unfortunately, toxicity of intraperitoneally administered nilotinib in combination with paclitaxel was observed, and higher-than-expected tumor growth resulted in a lack of power when the trial was analyzed. Thus, although lithium carbonate and IL-6-neutralizing antibodies tended toward neuroprotection, the differences between these groups were not statistically significant. However, the PINPRICS study ultimately still provides important lessons with regard to the planning and conduction of multicenter preclinical trials.
Authors
- Matthias Endres (ORCID: https://orcid.org/0000-0001-6520-3720)
- Frank Konietschke (ORCID: https://orcid.org/0000-0002-5674-2076)
- Petra Huehnchen (ORCID: https://orcid.org/0000-0002-6825-7270)
- Tim Hagenacker (ORCID: https://orcid.org/0000-0002-3631-3450)
- Helmar C. Lehmann (ORCID: https://orcid.org/0000-0001-6205-2293)
- Markus Leo (ORCID: https://orcid.org/0000-0002-3449-9829)
- Linda-Isabell Schmitt (ORCID: https://orcid.org/0000-0003-2506-1080)
- Ines Klein
- Regina Stegherr (ORCID: https://orcid.org/0000-0002-0528-348X)
- Wolfgang Boehmerle (ORCID: https://orcid.org/0000-0001-7195-3894)
Institutions
- German Center for Neurodegenerative Diseases (DE)
- Humboldt-Universität zu Berlin (DE)
- Essen University Hospital (DE)
- German Centre for Cardiovascular Research (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- University Hospital Cologne (DE)
Publication Details
- Journal
- BMC Research Notes
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1186/s13104-025-07206-2
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bundesministerium für Bildung und Forschung
- Charité – Universitätsmedizin Berlin